Boehringer Ingelheim: AH business in Asia

The joint venture, with investment totaling €58 million, will become a manufacturer of veterinary vaccines in Asia upon its completion. The facility is expected to complete construction in June 2015 and to create about 200 job opportunities.

“China is one of the most important Animal Health markets in the world. With the start of this project, we are fulfilling our commitment to providing the entire value chain of our vaccine business in China,” said Dr Joachim Hasenmaier, Member of the Board of managing directors and responsible for Animal Health: “Taizhou China Medical City proved to be an ideal partner for Boehringer Ingelheim. The project underlines our commitment of continued investment in China.”

Through this joint-venture, Boehringer Ingelheim is set to introduce leading Animal Health technology in China and to expedite the sector’s development in the country. The manufacturing plant will mainly produce vaccines for swine and poultry diseases.
Lu Chunyun, Standing Committee member of Taizhou municipal government and president of China Medical City, said: “Boehringer Ingelheim is a leading player in the world’s Animal Health sector, particularly in swine vaccines. China Medical City is the country’s only national level medical high-tech development park. This co-operation is set to create synergy and a win-win situation.”

“Boehringer Ingelheim’s vision is to become a reliable partner of choice for China’s animal breeders and to contribute to food safety in China,” said Dr Hasenmaier. “The Animal Health business together with our other strategic pillars – Prescription Medicines, Consumer Healthcare, Biopharmaceuticals and Operations – will continue to bring more health to China.”